The role of endoplasmic reticulum stress in the regulation of long noncoding RNAs in cancer
- PMID: 35959643
- DOI: 10.1002/jcp.30846
The role of endoplasmic reticulum stress in the regulation of long noncoding RNAs in cancer
Abstract
Cancer cells must overcome a variety of external and internal stresses to survive and proliferate. These unfavorable conditions include the accumulation of mutations, nutrient deficiency, oxidative stress, and hypoxia. These stresses can cause aggregation of misfolded proteins inside the endoplasmic reticulum. Under these conditions, the cell undergoes endoplasmic reticulum stress (ER-stress), and consequently initiates the unfolded protein response (UPR). Activation of the UPR triggers transcription factors and regulatory factors, including long noncoding RNAs (lncRNAs), which control the gene expression profile to maintain cellular stability and hemostasis. Recent investigations have shown that cancer cells can ensure their survival under adverse conditions by the UPR affecting the expression of lncRNAs. Therefore, understanding the relationship between lncRNA expression and ER stress could open new avenues, and suggest potential therapies to treat various types of cancer.
Keywords: ER stress; cell survival; long noncoding RNAs; signaling pathways; unfolded protein response (UPR).
© 2022 Wiley Periodicals LLC.
References
REFERENCES
-
- Alasiri, G., Jiramongkol, Y., Zona, S., Fan, L. Y.-N., Mahmud, Z., Gong, G., Lee, H. J., & Lam, E. W.-F. (2019). Regulation of PERK expression by FOXO3: A vulnerability of drug-resistant cancer cells. Oncogene, 38(36), 6382-6398.
-
- Araki, K., & Nagata, K. (2011). Protein folding and quality control in the ER. Cold Spring Harbor Perspectives in Biology, 3(11), a007526.
-
- Axten, J. M., Medina, J. S. R., Feng, Y., Shu, A., Romeril, S. P., Grant, S. W., Li, W. H. H., Heerding, D. A., Minthorn, E., & Mencken, T. (2012). Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl) phenyl] acetyl}-2,3-dihydro-1 H-indol-5-yl)-7H-pyrrolo [2, 3-d] pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). Journal of Medicinal Chemistry, 55(16), 7193-7207.
-
- Axten, J. M., Romeril, S. P., Shu, A., Ralph, J., Medina, J. R., Feng, Y., Li, W. H. H., Grant, S. W., Heerding, D. A., & Minthorn, E. (2013). Discovery of GSK2656157: An optimized PERK inhibitor selected for preclinical development. ACS Medicinal Chemistry Letters, 4(10), 964-968.
-
- Bagratuni, T., Wu, P., Gonzalez de Castro, D., Davenport, E. L., Dickens, N. J., Walker, B. A., Boyd, K., Johnson, D. C., Gregory, W., & Morgan, G. J. (2010). XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood, 116(2), 250-253.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
